Abstract
Objectives: In order to evaluate the effect of a medical administration for the sudden deafness patients, single-drug treatment for idiopathic sudden sensorineural hearing loss (ISSHL) was assessed at multi-centers participating in the Acute Severe Hearing Loss Study Group sponsored by the Ministry of Health, Labor and Welfare of Japan. Methods: The subjects consisted of ISSHL patients who were (1) 20 years of age or older, (2) diagnosed within 2 weeks after the onset of hearing loss, (3) showing a mean hearing level of 40-90 dB at five frequencies from 250 to 4000 Hz, (4) previously untreated, and (5) with normal for age in hearing of the opposite ear. The drugs used in this study were ATP, alprostadil, hydrocortisone and amidotrizoate, which were administered intravenously, and beraprost sodium and betamethasone, which were given orally. Two drugs were assigned to each center, one of which was selected according to the code hidden in envelopes and administered for 1 week. The treatment after the single-drug administration was conducted at the discretion of each center. The hearing gain and recovery rate at 1 week after the initiation of single-drug treatment and at 1 month or over when the hearing level was fixed, were evaluated based on the criteria for hearing recovery prepared by the Acute Severe Hearing Loss Study Group. Results: There was no statistically significant difference in the recovery rate among drugs either at 1 week after the initiation of single-drug treatment or at the time of fixed hearing level. At the time when the hearing level was fixed, a statistically significant difference in the complete recovery rate was detected only between amidotrizoate and beraprost sodium. Conclusion: From these results, we could not find any specific drugs recommended for ISSNHL. In evaluating the effect of the drugs, however, several problems in the clinical trial for ISSHL should be considered.
| Original language | English |
|---|---|
| Pages (from-to) | 123-127 |
| Number of pages | 5 |
| Journal | Auris Nasus Larynx |
| Volume | 30 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2003 May 15 |
Fingerprint
Keywords
- Idiopathic sudden sensori-neural hearing loss
- Multi-center trial
- Prognosis
- Single drug treatment
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Surgery
Cite this
Effect of single-drug treatment on idiopathic sudden sensorineural hearing loss. / Kanzaki, Jin; Inoue, Yasuhiro; Ogawa, Kaoru; Fukuda, Satoshi; Fukushima, Kunihiro; Gyo, Kiyofumi; Yanagihara, Naoaki; Hoshino, Tomoyuki; Ishitoya, Jun Ichi; Toriyama, Minoru; Kitamura, Ken; Murai, Kazuo; Nakashima, Tsutomu; Niwa, Hideto; Nomura, Yasuya; Kobayashi, Hitome; Oda, Makoto; Okamoto, Makito; Shitara, Tetuya; Sakagami, Masafumi; Tono, Tetsuya; Usami, Shin Ichi.
In: Auris Nasus Larynx, Vol. 30, No. 2, 15.05.2003, p. 123-127.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of single-drug treatment on idiopathic sudden sensorineural hearing loss
AU - Kanzaki, Jin
AU - Inoue, Yasuhiro
AU - Ogawa, Kaoru
AU - Fukuda, Satoshi
AU - Fukushima, Kunihiro
AU - Gyo, Kiyofumi
AU - Yanagihara, Naoaki
AU - Hoshino, Tomoyuki
AU - Ishitoya, Jun Ichi
AU - Toriyama, Minoru
AU - Kitamura, Ken
AU - Murai, Kazuo
AU - Nakashima, Tsutomu
AU - Niwa, Hideto
AU - Nomura, Yasuya
AU - Kobayashi, Hitome
AU - Oda, Makoto
AU - Okamoto, Makito
AU - Shitara, Tetuya
AU - Sakagami, Masafumi
AU - Tono, Tetsuya
AU - Usami, Shin Ichi
PY - 2003/5/15
Y1 - 2003/5/15
N2 - Objectives: In order to evaluate the effect of a medical administration for the sudden deafness patients, single-drug treatment for idiopathic sudden sensorineural hearing loss (ISSHL) was assessed at multi-centers participating in the Acute Severe Hearing Loss Study Group sponsored by the Ministry of Health, Labor and Welfare of Japan. Methods: The subjects consisted of ISSHL patients who were (1) 20 years of age or older, (2) diagnosed within 2 weeks after the onset of hearing loss, (3) showing a mean hearing level of 40-90 dB at five frequencies from 250 to 4000 Hz, (4) previously untreated, and (5) with normal for age in hearing of the opposite ear. The drugs used in this study were ATP, alprostadil, hydrocortisone and amidotrizoate, which were administered intravenously, and beraprost sodium and betamethasone, which were given orally. Two drugs were assigned to each center, one of which was selected according to the code hidden in envelopes and administered for 1 week. The treatment after the single-drug administration was conducted at the discretion of each center. The hearing gain and recovery rate at 1 week after the initiation of single-drug treatment and at 1 month or over when the hearing level was fixed, were evaluated based on the criteria for hearing recovery prepared by the Acute Severe Hearing Loss Study Group. Results: There was no statistically significant difference in the recovery rate among drugs either at 1 week after the initiation of single-drug treatment or at the time of fixed hearing level. At the time when the hearing level was fixed, a statistically significant difference in the complete recovery rate was detected only between amidotrizoate and beraprost sodium. Conclusion: From these results, we could not find any specific drugs recommended for ISSNHL. In evaluating the effect of the drugs, however, several problems in the clinical trial for ISSHL should be considered.
AB - Objectives: In order to evaluate the effect of a medical administration for the sudden deafness patients, single-drug treatment for idiopathic sudden sensorineural hearing loss (ISSHL) was assessed at multi-centers participating in the Acute Severe Hearing Loss Study Group sponsored by the Ministry of Health, Labor and Welfare of Japan. Methods: The subjects consisted of ISSHL patients who were (1) 20 years of age or older, (2) diagnosed within 2 weeks after the onset of hearing loss, (3) showing a mean hearing level of 40-90 dB at five frequencies from 250 to 4000 Hz, (4) previously untreated, and (5) with normal for age in hearing of the opposite ear. The drugs used in this study were ATP, alprostadil, hydrocortisone and amidotrizoate, which were administered intravenously, and beraprost sodium and betamethasone, which were given orally. Two drugs were assigned to each center, one of which was selected according to the code hidden in envelopes and administered for 1 week. The treatment after the single-drug administration was conducted at the discretion of each center. The hearing gain and recovery rate at 1 week after the initiation of single-drug treatment and at 1 month or over when the hearing level was fixed, were evaluated based on the criteria for hearing recovery prepared by the Acute Severe Hearing Loss Study Group. Results: There was no statistically significant difference in the recovery rate among drugs either at 1 week after the initiation of single-drug treatment or at the time of fixed hearing level. At the time when the hearing level was fixed, a statistically significant difference in the complete recovery rate was detected only between amidotrizoate and beraprost sodium. Conclusion: From these results, we could not find any specific drugs recommended for ISSNHL. In evaluating the effect of the drugs, however, several problems in the clinical trial for ISSHL should be considered.
KW - Idiopathic sudden sensori-neural hearing loss
KW - Multi-center trial
KW - Prognosis
KW - Single drug treatment
UR - http://www.scopus.com/inward/record.url?scp=0037659382&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037659382&partnerID=8YFLogxK
U2 - 10.1016/S0385-8146(03)00009-9
DO - 10.1016/S0385-8146(03)00009-9
M3 - Article
VL - 30
SP - 123
EP - 127
JO - Auris Nasus Larynx
JF - Auris Nasus Larynx
SN - 0385-8146
IS - 2
ER -